01—Abstract
Summary
Summary of the 10-K filed February 15, 2013. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories filed its 2012 10-K report on February 14, 2013, detailing its business segments and financial performance.
A significant event highlighted is the separation of its research-based pharmaceuticals business into a new independent company, AbbVie Inc., effective January 1, 2013. This separation reshapes Abbott's operational focus, with post-separation international sales expected to constitute a larger percentage of total revenue. The report outlines Abbott's diverse healthcare product portfolio, spanning Proprietary Pharmaceutical Products (largely spun off to AbbVie), Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.
The company emphasizes its commitment to research and development, investing billions annually to drive innovation across its segments. Regulatory compliance and managing healthcare cost containment efforts are noted as ongoing challenges. Financially, Abbott reported strong net sales and earnings for 2012.
The company highlights the robust growth of its key product, HUMIRA®, and strategic acquisitions like Solvay Pharmaceuticals and Piramal Healthcare's Healthcare Solutions business, which expanded its global presence, particularly in emerging markets. Despite facing some challenges, including pricing pressures in Europe and legal settlements, Abbott maintained a solid financial position.
02—Key points
Key Highlights
- Significant business transformation through the separation of its research-based pharmaceutical business into AbbVie Inc., effective January 1, 2013.
- Abbott's business segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products, post-AbbVie separation.
- Strong performance in 2012 with continued growth in key products like HUMIRA®.
- Investment in R&D remained substantial, totaling $4.3 billion in 2012 to support pipeline development across segments.
- Strategic acquisitions, including Solvay Pharmaceuticals and Piramal Healthcare's Healthcare Solutions business, expanded Abbott's global footprint and product offerings.
- The company is navigating a complex regulatory environment and ongoing healthcare cost containment efforts globally.
- Abbott maintains a strong financial position, with significant cash flow from operations and a stable debt rating.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2012, Abbott Laboratories kept $0.31.
- Revenue$19.05B100.0%
- Cost of revenue−$8.90B46.7%
- Gross profit$10.15B53.3%
- Operating costs−$8.79B46.1%
- Operating income$1.36B7.1%
- Interest, other & tax$4.56B23.9%
- Net income$5.92B31.1%
Where FY2012 revenue went
$19.05B- Cost of revenue: $8.90B, 47% of revenue
- SG&A: $6.74B, 35% of revenue
- Operating income: $1.36B, 7.1% of revenue
- Other operating costs: $2.06B, 11% of revenue
Kept 7.1% as operating incomeOperating income $1.36B · 7.1%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2012filed February 15, 2013Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $19.05B$21.41B | −11.0% |
| Cost of Revenue | $8.90B$10.02B | −11.2% |
| Gross Profit | $10.15B$11.39B | −10.9% |
| SG&A Expenses | $6.74B$7.37B | −8.6% |
| Operating Expenses | $17.69B$19.78B | −10.6% |
| Operating Income | $1.36B$1.63B | −16.5% |
| Interest Expense | $320.00M$359.00M | −10.9% |
| Net Income | $5.92B$4.71B | +25.5% |
| EPS (Basic) | $3.76$3.03 | +24.1% |
| EPS (Diluted) | $3.72$3.01 | +23.6% |
| Shares Outstanding (Basic) | 1.57B1.56B | +1.2% |
| Shares Outstanding (Diluted) | 1.59B1.57B | +1.6% |
05—Questions
Frequently Asked Questions
What is the most significant strategic change for Abbott Laboratories highlighted in this filing?
The most significant strategic change is the separation of Abbott's research-based pharmaceutical business into a new, independent publicly traded company called AbbVie Inc. This separation was completed on January 1, 2013, and it fundamentally reshapes Abbott's business focus moving forward.
What are Abbott's primary business segments after the separation of AbbVie?
Following the separation, Abbott's primary business segments are Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Vascular Products. The Proprietary Pharmaceutical Products segment, which included products like HUMIRA®, was largely transferred to AbbVie.
How did Abbott perform financially in 2012?
In 2012, Abbott reported strong financial results, with net sales and earnings demonstrating growth. The company highlighted substantial investment in research and development and successfully grew key product lines, alongside integrating recent strategic acquisitions.
What are some of the key risks and challenges mentioned in the report?
Key risks and challenges include patent expirations, competition from generic drugs, navigating complex and costly government regulations, managing healthcare cost containment efforts by governments and private organizations, potential product obsolescence due to technological advancements, and the inherent risks associated with research and development, where new product success is not guaranteed.
06—Continue